BRCA1 and GATA3 corepress FOXC1 to inhibit the pathogenesis of basal-like breast cancers

Oncogene

Volumn 31, Issue 32, 2012, Pages 3667-3678

  Tkocz, D ^a   Crawford, N T ^a   Buckley, N E ^a   Berry, F B ^b   Kennedy, R D ^a   Gorski, J J ^a   Harkin, D P ^a   Mullan, P B ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

basal like; BRCA1; corepression; FOXC1; GATA3

Indexed keywords

BRCA1 PROTEIN; MUTANT PROTEIN; P CADHERIN; TRANSCRIPTION FACTOR FOXC1; TRANSCRIPTION FACTOR FOXC2; TRANSCRIPTION FACTOR GATA 3;

ARTICLE; BASAL LIKE BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENE INTERACTION; GENE REPRESSION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION;

ANTINEOPLASTIC AGENTS; BASE SEQUENCE; BRCA1 PROTEIN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DRUG RESISTANCE, NEOPLASM; EPIRUBICIN; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; FLUOROURACIL; FORKHEAD TRANSCRIPTION FACTORS; GATA3 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; INHIBITORY CONCENTRATION 50; MITOMYCIN; MOLECULAR SEQUENCE DATA; NEOPLASMS, BASAL CELL; PHENOTYPE; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; RNA INTERFERENCE; TRANSCRIPTION, GENETIC;

EID: 84864915256     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.531     Document Type: Article

References (50)

1. Ademuyiwa FO, Thorat MA, Jain RK, Nakshatri H, Badve S. (2010). Expression of Forkhead-box protein A1, a marker of luminal A type breast cancer, parallels low Oncotype DX 21-gene recurrence scores. Mod Pathol 23: 270-275.
2. Albergaria A, Paredes J, Sousa B, Milanezi F, Carneiro V, Bastos J et al. (2009). Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours. Breast Cancer Res 11: R40.
3. Anderson SF, Schlegel BP, Nakajima T, Wolpin ES, Parvin JD. (1998). BRCA1 protein is linked to the RNA polymerase II holoenzyme complex via RNA helicase A. Nat Genet 19: 254-256.
4. Arnold JM, Choong DY, Thompson ER, Waddell N, Lindeman GJ, Visvader JE et al. (2010). Frequent somatic mutations of GATA3 in non-BRCA1/BRCA2 familial breast tumors, but not in BRCA1-, BRCA2-or sporadic breast tumors. Breast Cancer Res Treat 119: 491-496.
5. Asselin-Labat ML, Sutherland KD, Barker H, Thomas R, Shackleton M, Forrest NC et al. (2007). Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat Cell Biol 9: 201-209.
6. Berry FB, Skarie JM, Mirzayans F, Fortin Y, Hudson TJ, Raymond V et al. (2008). FOXC1 is required for cell viability and resistance to oxidative stress in the eye through the transcriptional regulation of FOXO1A. Hum Mol Genet 17: 490-505.
7. Bierie B, Stover DG, Abel TW, Chytil A, Gorska AE, Aakre M et al. (2008). Transforming growth factor-beta regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment. Cancer Res 68: 1809-1819.
8. Bloushtain-Qimron N, Yao J, Snyder EL, Shipitsin M, Campbell LL, Mani SA et al. (2008). Cell type-specific DNA methylation patterns in the human breast. Proc Natl Acad Sci USA 105: 14076-14081.
9. BocharDA, Wang L, Beniya H, KinevA, Xue Y, Lane WS et al. (2000). BRCA1 is associated with a human SWI/SNF-related complex: linking chromatin remodeling to breast cancer. Cell 102: 257-265.
10. Buckley NE, Conlon SJ, Jirstrom K, Kay EW, Crawford NT, O'Grady A et al. (2011). The {Delta}Np63 proteins are key allies of BRCA1 in the prevention of basal-like breast cancer. Cancer Res 71: 1933-1944.
11. Buckley NE, Hosey AM, Gorski JJ, Purcell JW, Mulligan JM, Harkin DP et al. (2007). BRCA1 regulates IFN-gamma signaling through a mechanism involving the type I IFNs. Mol Cancer Res 5: 261-270.
12. Campora E, Colloca G, Ratti R, Addamo G, Coccorullo Z, Venturino A et al. (2008). Docetaxel for metastatic breast cancer: two consecutive phase II trials. Anticancer Res 28: 3993-3995.
13. D'Anello L, Sansone P, Storci G, Mitrugno V, D'Uva G, Chieco P et al. (2010). Epigenetic control of the basal-like gene expression profile via Interleukin-6 in breast cancer cells. Mol Cancer 9: 300.
14. Dejeux E, Ronneberg JA, Solvang H, Bukholm I, Geisler S, Aas T et al. (2010). DNA methylation profiling in doxorubicin-treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response. Mol Cancer 9: 68.
15. Dydensborg AB, Rose AA, Wilson BJ, Grote D, Paquet M, Giguere V et al. (2009). GATA3 inhibits breast cancer growth and pulmonary breast cancer metastasis. Oncogene 28: 2634-2642.
16. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB et al. (2005). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434: 917-921.
17. Fedele CG, Ooms LM, Ho M, Vieusseux J, O'Toole SA, Millar EK et al. (2010). Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers. Proc Natl Acad Sci USA 107: 22231-22236.
18. Geyer FC, Lacroix-Triki M, Savage K, Arnedos M, Lambros MB, Mackay A et al. (2011). Beta-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation. Mod Pathol 24: 209-231.
19. Gorski JJ, James CR, Quinn JE, Stewart GE, Staunton KC, Buckley NE et al. (2010). BRCA1 transcriptionally regulates genes associated with the basal-like phenotype in breast cancer. Breast Cancer Res Treat 122: 721-731.
20. Hannenhalli S, Kaestner KH. (2009). The evolution of Fox genes and their role in development and disease. Nat Rev Genet 10: 233-240.
21. Hosey AM, Gorski JJ, Murray MM, Quinn JE, Chung WY, Stewart GE et al. (2007). Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer. J Natl Cancer Inst 99: 1683-1694.
22. Hoshino Y, Katsuno Y, Ehata S, Miyazono K. (2011). Autocrine TGF-beta protects breast cancer cells from apoptosis through reduction of BH3-only protein, Bim. J Biochem 149: 55-65.
23. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF et al. (2006). The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7: 96.
24. Jacquemier J, Charafe-Jauffret E, Monville F, Esterni B, Extra JM, Houvenaeghel G et al. (2009). Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer. Breast Cancer Res 11: R23.
25. Kalluri R, Weinberg RA. (2009). The basics of epithelial-mesenchymal transition. J Clin Invest 119: 1420-1428.
26. Kouros-Mehr H, Bechis SK, Slorach EM, Littlepage LE, Egeblad M, Ewald AJ et al. (2008). GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. Cancer Cell 13: 141-152.
27. Kouros-Mehr H, Slorach EM, Sternlicht MD, Werb Z. (2006). GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell 127: 1041-1055.
28. Kouroussis C, Xydakis E, Potamianou A, Giannakakis T, Kakolyris S, Agelaki S et al. (1999). Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: a multicenter dose-escalation study. The Greek Breast Cancer Cooperative Group (GBCCG). Ann Oncol 10: 547-552.
29. Laakso M, Loman N, Borg A, Isola J. (2005). Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors. Mod Pathol 18: 1321-1328.
30. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH et al. (2009). Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 15: 907-913.
31. Mani SA, Yang J, Brooks M, Schwaninger G, Zhou A, Miura N et al. (2007). Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. Proc Natl Acad Sci USA 104: 10069-10074.
32. Marchini C, Montani M, Konstantinidou G, Orru R, Mannucci S, Ramadori G et al. (2010). Mesenchymal/stromal gene expression signature relates to basal-like breast cancers, identifies bone metastasis and predicts resistance to therapies. PLoS One 5: e14131.
33. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S et al. (1994). A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266: 66-71.
34. Molyneux G, Geyer FC, Magnay FA, McCarthy A, Kendrick H, Natrajan R et al. (2010). BRCA1 Basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell 7: 403-417.
35. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T et al. (2006). A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10: 515-527.
36. Perou CM, Jeffrey SS, van de Rijn M, Rees CA, Eisen MB, Ross DT et al. (1999). Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA 96: 9212-9217.
37. Rasbridge SA, Gillett CE, Sampson SA, Walsh FS, Millis RR. (1993). Epithelial (E-) and placental (P-) cadherin cell adhesion molecule expression in breast carcinoma. J Pathol 169: 245-250.
38. Ray PS, Wang J, Qu Y, Sim MS, Shamonki J, Bagaria SP et al. (2010). FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer. Cancer Res 70: 3870-3876.
39. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H et al. (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869-10874.
40. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A et al. (2003). Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100: 8418-8423.
41. Tao L, Roberts AL, Dunphy KA, Bigelow C, Yan H, Jerry DJ. (2011). Repression of mammary stem/progenitor cells by P53 is mediated by Notch and separable from apoptotic activity. Stem Cells 29: 119-127.
42. Taube JH, Herschkowitz JI, Komurov K, Zhou AY, Gupta S, Yang J et al. (2010). Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci USA 107: 15449-15454.
43. Turner N, Tutt A, Ashworth A. (2004). Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 4: 814-819.
44. Usary J, Llaca V, Karaca G, Presswala S, Karaca M, He X et al. (2004). Mutation of GATA3 in human breast tumors. Oncogene 23: 7669-7678.
45. Wang HQ, Qian ZZ, Liu XM, Zhang HL, Li LF, Qiu LH et al. (2010). Capecitabine combined with weekly docetaxel in Chinese patients 465 years with anthracycline-resistant metastatic breast cancer. Chin Med J (Engl) 123: 3212-3216.
46. Wang Q, Zhang H, Kajino K, Greene MI. (1998). BRCA1 binds c-Myc and inhibits its transcriptional and transforming activity in cells. Oncogene 17: 1939-1948.
47. Yan W, Cao QJ, Arenas RB, Bentley B, Shao R. (2010). GATA3 inhibits breast cancer metastasis through the reversal of epithelialmesenchymal transition. J Biol Chem 285: 14042-14051.
48. Yang Q, Sakurai T, Mori I, Yoshimura G, Nakamura M, Nakamura Y et al. (2001). Prognostic significance of BRCA1 expression in Japanese sporadic breast carcinomas. Cancer 92: 54-60.
49. Yoon NK, Maresh EL, Shen D, Elshimali Y, Apple S, Horvath S et al. (2010). Higher levels of GATA3 predict better survival in women with breast cancer. Hum Pathol 41: 1794-1801.
50. Zhang H, Somasundaram K, Peng Y, Tian H, Bi D, Weber BL et al. (1998). BRCA1 physically associates with p53 and stimulates its transcriptional activity. Oncogene 16: 1713-1721.